Skip to main content
PLOS One logoLink to PLOS One
. 2026 Oct 1;21(10):e0359867. doi: 10.1371/journal.pone.0359867

Decision-theoretic recruitment and validation planning for depression surveys: An illustrative Chinese application

Han Liu 1,*
Editor: Jiaci Lin2
PMCID: PMC13630222  PMID: 42821577

Abstract

Background

Survey planning must balance recruitment losses against uncertainty in screening yield, diagnostic accuracy and survey design. This study examined how these considerations determine invitation requirements and diagnostic-validation allocation.

Methods

A Beta planning distribution used 170 PHQ-9-positive results among 1,045 Chinese community participants and an effective sample size of 100. Asymmetric recruitment loss selected conditional and joint-distribution invitation targets. A separate cost-plus-variance Bayes criterion jointly allocated survey clusters and independent reference-positive and reference-negative validation samples. Parameter uncertainty and future-data performance were evaluated by integration and simulation.

Results

With an illustrative underplanning-to-overplanning loss ratio of 3, conditional planning selected a screening-positive proportion of 0.1862 and 4,794 screening invitations. Integrating design uncertainty increased this target to 5,346. Current-prevalence planning required 9,247 conditional invitations or 11,866 under joint parameter uncertainty when diagnostic accuracy was known within each scenario. The original validation sample imposed a reference-point half-width floor of 0.0292, exceeding the 0.020 target. Under specified relative costs, the joint allocation used 21,708 invitations and 240/4,538 reference-positive/reference-negative validation participants. Its prior-predictive width attainment was 53.15%, compared with 0.03% when nearly the same budget retained the original validation sample. Increasing the precision valuation fourfold raised attainment to 10,000/10,000 simulations, with 95.31% coverage. Uncorrected specificity shifts produced substantial bias despite larger samples.

Conclusions

At k = 3, the loss-based rule selected a screening-positive planning proportion of 0.1862, reducing conditional invitation requirements by 39.38% relative to p = 0.5. Joint survey–validation allocation improved simulated precision at comparable assumed cost. These findings support allocating recruitment and diagnostic-validation resources jointly when planning current-prevalence surveys.

Introduction

Huang et al. [1] reported a weighted 12-month prevalence of major depressive disorder (MDD) of 2.1% (95% CI [1.8%, 2.4%]) among community-dwelling adults aged 18 years or older in the China Mental Health Survey, conducted in 2013–2015. A subsequent analysis documented substantial impairment and low treatment use among people with 12-month depressive disorders [2]. These findings motivate careful survey planning, but a 12-month disorder estimate does not determine the yield of a screener with a two-week symptom window. The national estimates therefore provide background only; none enters the numerical analysis.

For fixed precision, the usual sample-size formula for a proportion contains p(1−p) [3]. This term is maximised at p = 0.5 [3]. Thus, p = 0.5 gives the largest requirement over the full parameter space. The convention is appropriate when defensible prior information is unavailable or full-space protection is required. When expected positivity is low, however, it may increase recruitment without addressing misclassification, clustering or non-response. A lower planning value is defensible only when specified prospectively and evaluated under credible departures from its assumptions.

Bayesian sample-size methods have used posterior precision averaged over possible samples [4]. Binomial-proportion methods include average-coverage, average-length and worst-outcome criteria for highest posterior density intervals [5]. Generalised average-length and average-coverage criteria extend this framework [6]. Variance- and risk-based criteria have also been developed for conjugate binomial models [7]. Mixed Bayesian–likelihood criteria address comparisons of two proportions [8]. A decision-theoretic criterion instead assigns losses to the consequences of alternative sample sizes [9]. These approaches distinguish a precision requirement from a decision about the consequences of meeting or missing it.

Diagnostic uncertainty adds a variance contribution and an allocation decision. Bayesian prevalence planning has shown that uncertainty in misclassification rates can increase sample-size requirements and prevent a specified precision target from being reached [10]. Related methods address prevalence and diagnostic-test studies without a gold standard [11]. Testing strategies have also been compared by their accuracy and total cost [12]. The present application connects these established ideas to temporally aligned PHQ-9 evidence and clustered recruitment. It distinguishes conditional screening-loss decisions, decisions over the full invitation requirement, and allocation under a stated survey–validation cost-and-precision criterion.

The primary aim was to determine how aligned screening evidence and specified losses guide recruitment and diagnostic-validation allocation under uncertain diagnostic accuracy, clustering and response. A secondary aim was to quantify these decisions for two-week PHQ-9 positivity and current MINI-defined depression prevalence in an illustrative Chinese application, including comparisons with matched p = 0.5 designs.

Methods

Ethics approval and consent to participate

Not applicable. The study used published aggregate information and did not involve individual-level participant data.

Estimands and measurement relation

Two outcomes were specified. Screening positivity was defined as PHQ-9 ≥ 7, using the instrument’s preceding-two-week symptom window [13]. The current reference outcome was defined by the MINI depression assessment used in the Chinese validation study [14]. With indicators S2w and Dcur for these outcomes, the parameters were ps = P(S2w = 1), π = P(Dcur = 1), Se = P(S2w = 1 | Dcur = 1) and Sp = P(S2w = 0 | Dcur = 0). Screening positivity was calculated from the current-reference parameters by:

ps=P(PHQ−9≥7)=Seπ+(1−Sp)(1−π). (1)

The source protocol administered the PHQ-9 followed by the MINI depression assessment, and described the MINI reference classification in relation to current major depressive episodes [14]. Screening planning used the directly observed PHQ-9-positive count. Current-prevalence calculations used the same study’s MINI-positive count and threshold-specific accuracy estimates, with ps generated from Equation (1). S1 Appendix, Table S7 maps each empirical input to its outcome definition, source location and analytical use.

Decision-theoretic selection of the planning screening-positive proportion

The planning parameter was the future survey’s two-week PHQ-9 screening-positive proportion ps. A Beta distribution with shape parameters α > 0 and β > 0 represented planning uncertainty:

ps~Beta(α,β).

Define T=ps(1−ps), the component of binomial variance that depends on the proportion. Let T* ∈ [0, 0.25] be the value used for planning, co the unit loss assigned to oversampling and cu the unit loss assigned to under-recruitment relative to the target half-width. Both unit losses are strictly positive. The asymmetric absolute loss is

L(T*,T)=co(T*−T)++cu(T−T*)+,(x)+=max(x,0). (2)

The unrounded invitation requirement, with other inputs fixed, was proportional to T. The planning quantile was obtained by differentiating the expected loss in Equation (2): for candidate action a, the derivative was (co + cu)FT(a) − cu, where FT is the cumulative distribution function of T. Setting this derivative to zero gave:

q=cuco+cu=k1+k,k=cuco. (3)

The standard asymmetric linear-loss quantile rule was applied to the continuous variance term [15]. For t ∈ [0, 0.25], r(t) was defined as [1 − √(1 − 4t)]/2, and Fps denoted the Beta cumulative distribution function. The distribution of T was evaluated as:

FT(t)=Fps{r(t)}+1−Fps{1−r(t)}. (4)

Brent’s method solved FT(T*)=q. The two roots of T* = ps*(1 − ps*) give the same variance and invitation requirement. The lower root was selected for reporting in this low-positivity application:

ps*=1−1−4T*2. (5)

Planning prior and updating

At PHQ-9 ≥ 7, the validation study reported 170 positive results among 1,045 residents of one Shanghai community [14]. These counts set the planning mean to μs = 170/1,045 = 0.162679. An investigator-specified effective sample size (ESS) of 100 discounted the source sample, giving α = 100μs = 16.2679426 and β = 100(1 − μs) = 83.7320574. Full-precision parameters were used in all calculations.

For the local-update extension, the binomial likelihood for x screening-positive results among n independent pilot participants was combined with the planning prior:

ps∣x~Beta(α+x,β+n−x). (6)

Loss-ratio specification

The base calculation specified an underplanning-to-overplanning marginal loss ratio k = 3, corresponding to q = 0.75. Loss-ratio sensitivity recalculated the quantile, planning proportion and invitation requirements at k = 1, 2, 3, 5, 10 and 20. These investigator-specified values were fixed before performance evaluation. A prospective elicitation template is provided in S1 Appendix, Section S10.

Estimand-specific sample-size formulae

The anticipated mean analysed cluster size m̄, its coefficient of variation CVm and the screening-outcome intraclass correlation ρ defined the clustering adjustment. Under exchangeable outcomes and noninformative cluster sizes, the respondent-weighted factor 1 + ρ[Σ mc2/Σ mc − 1] was expressed using the cluster-size moments as:

DEFF=1+ρ[(1+CVm2)m¯−1]. (7)

Equation (7) used the unequal-cluster expression studied in cluster-randomised-trial planning [16]. Setting CVm = 0 gave the equal-cluster factor 1 + ρ(m̄ − 1) [17]. The other inputs were anticipated response RR, target 95% confidence-interval half-width d and z = 1.96. The candidate used ps,plan = ps*, and its comparator used ps,plan = 0.5. The final invitation requirement was rounded upward once using the ceiling operator.

For screening positivity ps, the invitation requirement was calculated as:

ninv,s=ceil{z0.9752ps,plan(1−ps,plan)DEFFd2RR}. (8)

For current reference prevalence, screening positivity was adjusted using the Rogan–Gladen estimator with fixed sensitivity and specificity [18]:

π^=p^s+Sp^−1Se^+Sp^−1,

where J=Se+Sp−1. Treating Se and Sp as fixed gives

ninv,π(fixed)=ceil{z0.9752ps,plan(1−ps,plan)DEFFd2RRJ2}. (9)

The conditional current-prevalence candidate substituted ps* from the screening-loss calculation into Equation (9). Its performance was then evaluated under a joint distribution of current prevalence and diagnostic accuracy, generating ps from Equation (1) for each draw. Both estimands used d = 0.020 and untruncated normal-approximation intervals. The fixed-accuracy reference-point comparison used ps,plan = ps,0.

Diagnostic-accuracy uncertainty and the precision floor

The diagnostic-variance calculation was evaluated at a coherent reference point: ps,0 = Seπ0 + (1 − Sp)(1 − π0). The delta method was applied to g(ps, Se, Sp) = (ps + Sp − 1)/(Se + Sp − 1), using gradient (1, − π0, 1 − π0)/J. The survey, validation and cross-sample components were calculated as:

Vs=Var(p^s)≈ps,0(1−ps,0)DEFFninvRR,
VD(π0)=π02Var(Se^)+(1−π0)2Var(Sp^)−2π0(1−π0)Cov(Se^,Sp^),

and

VSV(π0)=−2π0Cov(p^s,Se^)+2(1−π0)Cov(p^s,Sp^).

Then

Var(π^)≈J−2{Vs+VD(π0)+VSV(π0)}. (10)

The reference scenario used π0 = 28/1,045 and rounded Se = Sp = 0.86 from the Shanghai study [14]. Equation (1) then gave ps,0 = 0.1592919. All variance components were evaluated at this point. Validation was modelled as an external sample independent of the survey, with independent-binomial accuracy estimates conditional on fixed reference-positive and reference-negative denominators n1 and n0. Accordingly, VSV and Cov(Sê, Sp̂) were set to zero, giving:

VD(π0)=π02Se(1−Se)n1+(1−π0)2Sp(1−Sp)n0.

For each fixed independent-validation allocation, the main-survey requirement was calculated as:

ninv,π(ext)=ceil{ps,0(1−ps,0)DEFFRR[d2J2/z0.9752−VD(π0)]}. (11)

For J > 0 and 0 < ps,0 < 1, the available survey-variance budget was calculated as B = d2J2/z2 − VD(π0). Equation (11) was evaluated when B > 0; otherwise, the requirement was recorded as infinite. The limiting first-order half-width was calculated as z√VD(π0)/J.

The fixed-accuracy lower bound was checked by evaluating Equations (9) and (11) at the same ps,0, d, DEFF, RR, Se and Sp. At VD(π0) = 0 the formulae coincide. For 0 < VD(π0) < d2J2/z2, the positive validation term reduces the survey-variance budget and increases the unrounded requirement; upward rounding preserves the ordering. At or above this boundary, the positive survey-variance component prevents a finite solution. This comparison used the coherent reference point in both formulae.

Sampling and validation assumptions

The base calculations used exchangeable screening outcomes, noninformative cluster sizes, outcome-independent response and diagnostic accuracy defined for the target screening and reference classifications. Covariance terms were retained in Equation (10) and set to zero for the independent external-validation calculations. Independence between prior marginals was specified separately for the base integration analyses.

Illustrative Chinese depression-surveillance application

The base case specified d = 0.020, Se = Sp = 0.86, ρ = 0.03, m̄ = 50, CVm = 0, RR = 0.75, ESS = 100 and k = 3. The PHQ-9 threshold, positivity count, validation denominators and rounded diagnostic-accuracy estimates came from the Shanghai study [14]. Precision, clustering, response, prior strength, losses and sensitivity distributions were investigator-selected inputs. The comparator changed only ps,plan to 0.5. Percentage difference was calculated as 100 × [1 − n(ps*)/n(0.5)].

Sensitivity analyses

ESS sensitivity used 5, 10, 25, 50, 100 and 200 while holding the planning mean at 170/1,045. Prior-location sensitivity used means 0.10, 0.13, 170/1,045, 0.20 and 0.25 at ESS 100. The alternative logit-normal distributions fixed logit-location at logit(170/1,045), giving probability-scale median 170/1,045, and used logit-scales τ = 0.05, 0.15, 0.30, 0.50 and 0.75. Each specified distribution was transformed to T, and the same quantile rule and sample-size formulae were applied.

Specificity sensitivity used Sp = 0.86, 0.84, 0.82, 0.80 and 0.78 at Se = 0.86 and π0 = 28/1,045. Each scenario recalculated the model-implied screening mean, its ESS-100 Beta distribution, the planning quantile and J-2. This scenario series used the rounded-accuracy model mean, whereas the primary prior used observed positivity. Validation sensitivity retained n1 = 28 and varied n0 over 1,017, 2,500, 5,000 and 10,000. Analytical boundaries varied one parameter at a time while holding the other formula inputs fixed.

The source-consistency check enumerated integer diagnostic tables compatible with the published margins and sensitivity and specificity rounded to two decimals. Predictive values and likelihood ratios calculated from each compatible table were compared with the published summaries. The rounding analysis evaluated the four corners of [0.855, 0.865]2. It held the observed-positivity prior, ps*, π0 and survey-design inputs fixed, recalculated J and coherent ps,0, and recomputed candidate invitations and the validation floor.

Joint parameter assurance

For estimand e, let ne(k) be the candidate invitation count and Nreq,e(θ) the formula-based requirement at planning parameters θ. Parameter assurance was defined as:

Ae(k)=Pθ{Nreq,e(θ)≤ne(k)}. (12)

For each candidate, Equation (12) was estimated as the fraction of parameter draws whose formula-based requirement did not exceed the candidate invitation count. The resulting parameter assurance was compared with a prespecified 0.90 benchmark. Predictive interval-width attainment was evaluated separately by generating future survey and validation data.

For screening positivity, the specified marginals were ps ~ Beta(100 × 170/1,045, 100 × 875/1,045), ρ ~ Triangular(0.02, 0.03, 0.05) and RR ~ Triangular(0.60, 0.75, 0.85). For current reference prevalence, they were π ~ Triangular(0.01, 28/1,045, 0.10), Se ~ Triangular(0.78, 0.86, 0.90) and Sp ~ Triangular(0.80, 0.86, 0.90), with the same ρ and RR distributions. Triangular arguments denote minimum, mode and maximum. Each current-prevalence draw generated screening positivity through Equation (1).

Independent marginals defined the base joint distribution. A PCG64 stream with seed 20260722 generated 1,000,000 draws per estimand, with screening draws generated first. Each draw’s Se and Sp values were inserted into the fixed-accuracy requirement in Equation (9). The resulting requirements were used to evaluate conditional candidates and calculate joint recruitment-loss decisions.

Bayes decisions under joint uncertainty

At each joint-distribution draw θ, Equation (8) or (9) was rounded upward to obtain the integer requirement Re(θ). The loss was specified as co(n − Re)₊ + cu(Re − n)₊. Under finite E(Re), its Bayes action was calculated as the smallest integer reaching the q-quantile:

nq = min{n ∈ N : FRe(n) ≥ q},     q = k1+k. (13)

Equation (13) was evaluated for the same six k values and for the 0.90 assurance benchmark, corresponding to k = 9. The empirical inverse CDF of the 1,000,000 integer requirements was calculated without interpolation. S1 Appendix gives the integer-loss derivation and the finite-risk conditions.

Joint allocation of survey and validation samples

The current-prevalence allocation action was x = (C, n1, n0), with integers C, n1, n0 ≥ 2. C denoted survey clusters, and n1 and n0 denoted independent reference-positive and reference-negative validation counts. Each cluster received b = 67 invitations. Conditional on θ = (π, Se, Sp, ρ, RR), the first-order ratio-estimator variance under Bernoulli response and exchangeable screening outcomes was calculated as:

V(x; θ) = aC(θ)C + a1(θ)n1 + a0(θ)n0. (14)

The coefficients were aC = ps(1 − ps)[1 + (b − 1)RRρ]/(b RR J2), a1 = π2Se(1 − Se)/J2 and a0 = (1 − π)2Sp(1 − Sp)/J2. Screening positivity was calculated using Equation (1). The survey coefficient used binomial respondent counts at fixed b; the validation coefficients used conditional binomial sampling variances. Coefficient expectations were integrated over the previously specified current-prevalence joint prior.

The allocation loss was specified as total cost plus λ times first-order estimation variance. With positive unit costs c = (cC, c1, c0), λ > 0 and āj = Eθ[aj(θ)], the Bayes risk was:

R(x)=Σjcjxj+λΣja―jxj,  x=(C,n1,n0). (15)

For each component, the continuous minimiser xj* = √(λāj/cj) was calculated. Its floor and ceiling were evaluated after applying the lower bound xⱼ ≥ 2, and the lower-risk integer was selected; ties selected the smaller count. S1 Appendix provides the convexity proof, the continuous fixed-budget allocation and the numerical optimality checks.

Illustrative all-inclusive costs were set to one relative unit per invitation and five per completed validation participant, giving c = (67, 5, 5). The base precision valuation was calibrated as λ0 = [Σj√(cjāj)/v0]2, where v0 = (d/z)2, setting the continuous allocation’s prior mean variance to v0. Coefficient expectations used Gauss–Legendre quadrature split at triangular modes, with convergence checked at 32 and 48 nodes per segment. The integer allocation’s expected variance was recalculated after optimisation.

Allocation sensitivity used λ/λ0 = 0.25, 0.5, 1, 2 and 4. Cost sensitivity used (c1, c0) = (1,1), (5,5), (20,5) and (5,20), holding λ0 and invitation cost fixed. Prior sensitivity preserved triangular marginals while separately setting latent Gaussian-copula correlation to −0.5 for Se/Sp or ρ/RR. A wider-accuracy scenario used Se ~ Triangular(0.60,0.86,0.95) and Sp ~ Triangular(0.75,0.86,0.95). Each scenario used 1,000,000 parameter draws. The reoptimised allocation and the unchanged base design were evaluated under each applicable prior scenario.

Cluster simulation operating characteristics

Cluster simulation evaluated three planning values for current reference-standard prevalence: ps* = 0.1862346, ps = 0.30 and ps = 0.50. Their fixed-accuracy invited samples were 9,247, 12,813 and 15,254. For each strategy, C = ceil(ninv × 0.75/50) gave 139, 193 and 229 clusters. Invitations were divided as evenly as possible. One additional invitation was assigned to each of the first remainder clusters. The cluster counts and invitation allocations were held fixed across scenarios.

Cluster screening-positive risks followed Beta(a,b), where a = ps(ρ-1−1) and b = (1 − ps)(ρ-1−1). Respondent counts were binomial with the scenario response probability. Screening-positive counts were binomial conditional on respondent counts and cluster risk.

Let Yc and Nc denote screening-positive and respondent counts in cluster c. For C clusters, the screening variance estimate was [C/(C − 1)]Σc(Yc − p̂s Nc)2/(Σc Nc)2 The untruncated Rogan-Gladen estimate and normal interval used either true scenario-specific accuracy or unrecalibrated Se = Sp = 0.86. Width attainment was the fraction of replicates with half-width ≤0.020 using true scenario accuracy. Coverage was reported separately for both analyses.

Departures comprised π = 0.10, Sp = 0.80, Se = 0.78, or the joint change ρ = 0.05 and RR = 0.60. The combined adverse scenario used π = 0.05, Se = Sp = 0.80, ρ = 0.05 and RR = 0.60.

Informative response used logit(RRc) = ar − 0.75 zc. Within each replicate, zc was centred and scaled by the sample mean and standard deviation of cluster risk; ar was chosen to give an invitation-weighted response probability of 0.75. Each of the 21 scenario-strategy cells used 10,000 replicates and a separate child stream from seed 20260722.

Finite-validation and transportability simulations

The finite-validation simulations evaluated the integer allocations at λ0 and 4λ0 and a comparator retaining n1 = 28 and n0 = 1,017. The comparator allocated the remaining base-design budget to complete 67-invitation clusters. For each replicate, cluster screening risks were beta-distributed with mean ps and ICC ρ. Respondent counts followed Binomial(67, RR), and screening-positive counts were binomial conditional on respondents and cluster risk. Independent true-positive and true-negative validation counts followed Binomial(n1, Seval) and Binomial(n0, Spval). The Rogan–Gladen estimate used the resulting estimated accuracy. Its untruncated interval combined the cluster variance estimate with the two plug-in validation components from Equation (14).

Each of 15 design–scenario cells used 10,000 replicates. Scenarios were the reference point; draws of all five parameters from the base joint prior; target Sp = 0.80 with source validation Seval = Spval = 0.86; the same target with local validation Spval = 0.80; and target Se = 0.78 with source validation retained at 0.86. Non-positive estimated J or an undefined interval counted as both width and coverage failure. Outcomes were width attainment, coverage, their joint occurrence, bias and mean squared error. The prior-predictive scenario integrated parameter and future-data uncertainty; the others evaluated fixed departures.

An analytical transportability grid additionally crossed ΔSe = 0, −0.04, −0.08 with ΔSp = 0, −0.02, −0.06 at π0, relative to source accuracy 0.86. The limiting bias when source accuracy is retained is [π0ΔSe − (1 − π0)ΔSp]/Jsource. S1 Appendix gives the complete grid and simulation recipe. New random streams used SeedSequence([20260722, 20260907, s]); s = 1 for base allocation draws, 2–4 for prior sensitivity, and 19 with 15 spawned child streams for future-data simulations.

The analysis used Python 3.12.13, NumPy 2.3.5, pandas 2.2.3, SciPy 1.17.0 and Matplotlib 3.10.8. Independent checks covered loss integration, a uniform-prior closed form, numerical derivatives, variance budgets, quadrature convergence and integer optimality. Monte Carlo standard errors and Wilson intervals were reported for simulated proportions, including zero-event cells. S1 Appendix provides proofs, exact simulation settings and the output-file map.

Results

Planning value and base-case sample sizes

At k = 3, the conditional loss rule selected T* = 0.1515513 and the lower-root planning value ps* = 0.1862346. This value is neither the prior mean 0.1627 nor an estimate of disorder prevalence. With design effect 2.47, screening positivity required 4,794 invitations, compared with 7,908 under p = 0.5.

Current reference-standard prevalence required 9,247 invitations when Se = Sp = 0.86 were treated as known, compared with 15,254 under matched p = 0.5 planning (Table 1). Both conditional differences were 39.38%. These comparisons hold all design inputs fixed.

Table 1. Base-case invited sample size by estimand and planning proportion.

Estimand Planning input Invitations Difference from p = 0.5
PHQ-9 positivity ps* = 0.1862 4,794 39.38% smaller
PHQ-9 positivity p = 0.5000 7,908 Reference
Current reference prevalence ps* = 0.1862 9,247 39.38% smaller
Current reference prevalence p = 0.5000 15,254 Reference

Note. All calculations use d = 0.02, ρ = 0.03, a mean of 50 analysed respondents per cluster, cluster-size CV = 0 and RR = 0.75. The current-prevalence rows treat Se = Sp = 0.86 as fixed. The same numerical d is illustrative and does not make the two estimands substantively equivalent.

Recruitment under parameter uncertainty

Increasing the relative loss for under-recruitment increased the planning value and conditional sample requirement (Table 2). Across k ∈ {1, 2, 3, 5, 10, 20}, ps* ranged from 0.1604 to 0.2278. The screening-positive requirement ranged from 4,261–5,564. The fixed-accuracy current-prevalence requirement ranged from 8,218–10,732. Relative to p = 0.5, the corresponding conditional differences decreased from 46.12% to 29.64% for screening positivity. They decreased from 46.13% to 29.64% for current reference-standard depression. No empirical cost evidence distinguished k = 3 from the other prespecified values.

Table 2. Candidate loss-ratio designs and joint parameter assurance.

k (q) ps* Screening invitations Screening parameter assurance Current-prevalence invitations Current-prevalence parameter assurance
1 (0.5000) 0.1604 4,261 37.24% 8,218 16.43%
2 (0.6667) 0.1767 4,601 50.22% 8,876 26.59%
3 (0.7500) 0.1862 4,794 57.37% 9,247 32.98%
5 (0.8333) 0.1981 5,024 65.34% 9,691 40.88%
10 (0.9091) 0.2134 5,310 74.02% 10,242 50.65%
20 (0.9524) 0.2278 5,564 80.47% 10,732 58.86%

Note. Parameter assurance evaluates the formula-based requirement under the stated independent marginal distributions; it does not integrate future data. Current-prevalence draws derive ps from π, Se and Sp and treat those accuracy values as known. With 1,000,000 draws, the maximum Monte Carlo standard error is 0.0005. Finite validation variance is assessed separately.

Under the specified joint distributions, parameter assurance increased with k but remained below 0.90 for all six candidates (Table 2). Screening assurance ranged from 37.24% to 80.47%; current-prevalence assurance ranged from 16.43% to 58.86%. At k = 3, the corresponding values were 57.37% and 32.98%. These are probabilities that a formula-based requirement fits the candidate size under parameter uncertainty, not the base-scenario simulated width-attainment probability of 84.11%.

Applying the same k = 3 recruitment loss to the full uncertain requirement selected 5,346 screening invitations and 11,866 oracle-accuracy current-prevalence invitations. The corresponding parameter assurances were 75.01% for both estimands, compared with 57.37% and 32.98% for the original conditional candidates. The declared 90% benchmark required 6,089 and 13,551 invitations. These values use the complete requirement distribution rather than a variance quantile multiplied by fixed design factors.

Prior sensitivity

Prior strength affected the calculation. At mean 170/1,045 and k = 3, reducing ESS from 100 to 5 increased ps* from 0.1862 to 0.2389. The fixed-accuracy current-prevalence sample increased from 9,247–11,094. At ESS 200, ps* = 0.1796 and the sample was 8,992 (Fig 1A). Varying the prior mean from 0.10 to 0.25 at ESS 100 changed the sample from 6,376–12,254. Sensitivity under the logit-normal model also depended on τ. Increasing τ from 0.05 to 0.30 raised ps* from 0.1673 to 0.1922. The sample increased from 8,501–9,472. At τ = 0.75, ps* = 0.2436 and the sample was 11,244. These results confirm that the prescribed distribution is a discounted planning input rather than a posterior identified by one study.

Fig 1. Sensitivity to planning-distribution ESS and specificity.

Fig 1

Panel A holds the prior mean at the directly observed PHQ-9-positive proportion 170/1,045 and k = 3. Panel B reconstructs screening positivity from current reference-standard prevalence and recalculates both the prior location and diagnostic inflation as specificity changes, with sensitivity fixed at 0.86.

Diagnostic accuracy, transportability and validation precision

Specificity affected both model-implied screening positivity and variance inflation (Table 3; Fig 1B). At Sp = 0.86 and π0 = 28/1,045, the reconstructed mean was 0.1593 and the candidate requirement was 9,108. The principal observed-positivity prior instead gave 9,247. Reducing specificity to 0.80 increased the reconstructed mean to 0.2177, ps* to 0.2444 and the requirement to 13,411. At Sp = 0.78, the requirement was 15,035, compared with 19,305 under the matched p = 0.5 design. This 22.12% difference holds diagnostic accuracy constant between strategies.

Table 3. Specificity-recalibrated planning values.

Planning Sp Model-implied prior mean ps Selected ps* Fixed-accuracy invitations
0.86 0.1593 0.1826 9,108
0.84 0.1788 0.2033 10,457
0.82 0.1982 0.2239 11,888
0.80 0.2177 0.2444 13,411
0.78 0.2371 0.2648 15,035

At the coherent reference point π₀ = 28/1,045 and ps,0 = 0.1592919, the independent-binomial validation model imposed a minimum 95% half-width of 0.0292199 (Fig 2). The finite-validation precision budget was therefore negative at d = 0.020, so Equation (11) had no finite solution. Specificity contributed 97.32% of diagnostic variance. Increasing only n0 to 2,500 reduced the floor to 0.0189973 and required 83,583 main-survey invitations. Values n0 = 5,000 and 10,000 required 15,705 and 11,170 invitations. These are pointwise reference-scenario requirements, rather than the loss-based candidate sizes in Table 1; the complete calculation is supplied in validation_precision.csv.

Fig 2. Validation sample size and the precision limit for current prevalence.

Fig 2

The curve shows the minimum attainable 95% confidence-interval half-width for current reference-standard prevalence as the reference-negative validation sample increases. The reference-positive validation sample remains fixed at 28. The horizontal line is the prespecified 0.020 target; π₀ = 28/1,045 and Se = Sp = 0.86.

The source reports a positive predictive value of 0.15 at PHQ-9 ≥ 7 [14]. Under one unweighted diagnostic table with the published margins, sensitivity rounding to 0.86 implies 24 true positives, giving 24/170 = 0.1412, which rounds to 0.14. The published summaries therefore did not establish an exact internally consistent diagnostic table. Predictive values were excluded from the planning inputs. Across the diagnostic-rounding enclosure, fixed-accuracy candidate invitations ranged from 8,996–9,509, and the coherent validation floor ranged from 0.02838 to 0.03007. The 0.020 target remained unattainable with the fixed validation sample throughout this enclosure.

Simulated width attainment, coverage and failure boundaries

The 9,247-invitation candidate attained the 0.020 interval-width target in 84.11% of base-scenario replicates (Table 4). Width attainment was 22.94% at π = 0.10, 1.55% at Sp = 0.80 and 23.98% at Se = 0.78. It was 2.75% under the adverse ICC-response scenario. The p = 0.50 design attained 98.31%−100% across these single-departure scenarios. Under the combined adverse condition, all three strategies recorded 0 successes in 10,000 replicates. These empirical zeros do not establish a zero underlying probability.

Table 4. Simulated width attainment and coverage under parameter misspecification.

Scenario Width attainment: ps* Width attainment: p = 0.30 Width attainment: p = 0.50 Base-accuracy coverage: ps*
Base case 0.8411 1.0000 1.0000 0.9480
π = 0.10 0.2294 0.9889 1.0000 0.9507
Sp = 0.80 0.0155 0.6473 0.9861 0.0000
Se = 0.78 0.2398 0.9807 1.0000 0.9300
ρ = 0.05; RR = 0.60 0.0275 0.6661 0.9831 0.9462
Informative response 0.9958 1.0000 1.0000 0.5343
Combined adverse 0.0000 0.0000 0.0000 0.0000

Note. Width attainment is the fraction of 10,000 replicates with untruncated 95% half-width ≤0.020 using scenario-specific accuracy. The final column uses the unrecalibrated base accuracy. A displayed zero represents 0/10,000, not a proven zero probability; its two-sided 95% Wilson upper bound is approximately 0.000384. The maximum Monte Carlo standard error is 0.005. Finite validation uncertainty is excluded.

With Sp = 0.80, the candidate’s coverage was 94.79% when the analysis used the correct scenario accuracy, but 0/10,000 when it retained Se = Sp = 0.86. Under informative response, width attainment was at least 99.58%, yet coverage was 53.43%, 40.80% and 35.30% for the three strategies (Fig 3). Thus, a narrow interval could coexist with substantial selection bias. In the correctly specified, noninformative candidate scenarios, true-accuracy coverage ranged from 94.42% to 95.07%; full results and Monte Carlo intervals are provided in the simulation output.

Fig 3. Cluster-simulation operating characteristics.

Fig 3

Panel A shows interval-width attainment using scenario-specific diagnostic accuracy; its dashed line marks 90%. Panel B shows coverage when the analysis retains Se = Sp = 0.86; its dashed line marks 95%. Each cell uses 10,000 replicates. Bars include 95% Monte Carlo Wilson intervals.

Under the fixed formula inputs, the 9,247-invitation design met the pointwise target on the low-positivity branch while ps ≤ 0.186245, equivalent to π ≤ 0.064229. At π = 28/1,045, the corresponding largest ICC was 0.036640 and smallest response rate was 0.662708.

These boundaries hold analysed mean cluster size at 50. The simulation instead fixes cluster count, allowing response changes to alter realised cluster size; the two calculations therefore address different allocation assumptions.

The original validation sample imposed a precision constraint that no change in k could remove at the reference point. The extended allocation analysis therefore treated validation capacity as a design variable. The original loss-ratio graphic is retained as Fig S1 in S1 Appendix.

Joint allocation and future-data performance

Under the joint cost-plus-variance criterion, the base optimum was 324 clusters, 21,708 invitations, 240 reference-positive and 4,538 reference-negative validation participants. Its cost was 45,598 relative units. The rounded optimum had 1.96√E(V) = 0.020003 and parameter assurance of 53.72%; prior-predictive width attainment was 53.15% and coverage was 95.05%. Retaining the original validation counts at nearly the same cost (45,559 units) allowed 40,334 invitations but produced 0.03% predictive width attainment and 95.44% coverage (Table 5).

Table 5. Joint allocation and prior-predictive performance.

Design Invitations Validation n1 / n0 Relative cost Width attainment Coverage
Joint, λ0 21,708 240 / 4,538 45,598 0.5315 0.9505
Joint, 4λ0 43,416 481 / 9,077 91,206 1.0000 0.9531
Fixed validation, matched budget 40,334 28 / 1,017 45,559 0.0003 0.9544

Note. Width attainment and coverage integrate the stated parameter prior and future survey/validation data, with 10,000 replicates per row. Costs use one unit per invitation and five per completed validation participant. The matched-budget comparator costs 39 units less because clusters are indivisible. Values 0.0003 and 1.0000 represent 3 and 10,000 successes. These are different designs from the oracle-accuracy calculations in Tables 1–4.

At 4λ0, the optimum used 648 clusters, 43,416 invitations and validation counts of 481/9,077, costing 91,206 units. Width attainment was 10,000/10,000 and coverage was 95.31% in the prior-predictive simulation. The two-sided 95% Wilson lower bound for the universal width-success count was 99.96%, so the simulation does not establish a true success probability of one. Fig 4 contrasts joint allocation with spending on the survey while keeping validation fixed.

Fig 4. Joint survey–validation allocation and precision.

Fig 4

Panel A compares the continuous minimum prior mean variance at each assumed budget with retaining 28/1,017 validation participants. The plotted quantity is 1.96√E(V), not an expected realised interval width. Panel B reports prior-predictive width attainment and coverage for the three designs in Table 5; bars show 95% Monte Carlo Wilson intervals. Costs are illustrative relative units.

Accuracy shifts affected validity as well as precision. With target specificity 0.80 and source validation retained at 0.86, limiting bias was + 0.0811 at π0. At 4λ0, simulated width attainment remained 100%, but coverage was 0/10,000. Local validation at target specificity restored coverage to 94.83%. Wider accuracy priors changed the reoptimised counts to 23,718 invitations and 294/4,993 validation participants; the unchanged base design’s parameter assurance fell to 40.54%. Full cost, dependence and transportability results are supplied in S1 Appendix and the numerical output.

Discussion

The calculations show how recruitment decisions change when uncertainty is integrated into the decision itself. At k = 3, the conditional screening-loss rule produced 4,794 screening invitations, whereas loss on the full requirement produced 5,346 after integrating clustering and response. The corresponding current-prevalence values were 9,247 and 11,866 under oracle diagnostic accuracy. Thus, the 39.38% difference from conditional p = 0.5 calculations describes a fixed-input comparison; it does not quantify the gain from a complete uncertain-input design.

The decision-theoretic contribution is the explicit separation of objectives and action spaces. The quantile rule is established decision theory [15]. Applying it to the entire invitation requirement gives a Bayes recruitment decision under the specified joint distribution. It cannot assign costs to validation, and an infinite requirement with positive prior probability makes its expected shortfall loss infinite. The cost-plus-variance criterion supplies a finite, explicitly defined alternative that allocates survey clusters and both validation strata jointly. Its global optimum is proved for the stated first-order risk, rather than asserted for every design objective.

Validation allocation had a larger effect than adding main-survey invitations in the evaluated budget comparison. At relative costs of 45,598 and 45,559 units, joint allocation achieved 53.15% prior-predictive width attainment, whereas retaining the original validation sample achieved 0.03% despite 40,334 invitations. This result follows from the three separate variance components: more survey clusters reduce only the survey component. The reference-point specificity contribution of 97.32% also depends on the validation allocation. With both strata free to vary, the optimum balances marginal precision per cost unit; it does not imply that specificity is universally the only validation priority.

The allocation model uses independent external validation, a setting for which adjusted-prevalence intervals have been studied [19]. Validation nested within the main survey introduces a different sampling problem because phase-two selection enters prevalence estimation [20]. The budget comparison therefore addresses the external-validation design specified here.

A Bayes optimum remains specific to its utility. The base allocation was calibrated to a continuous-design prior mean variance corresponding to d = 0.020, yet its predictive width attainment was 53.15%. Increasing λ to 4λ0 produced 10,000/10,000 width successes and 95.31% coverage under the stated prior-predictive model. This improvement required approximately twice the assumed total cost. The comparison does not identify an empirically correct λ or k; a probability-of-success requirement should be declared as a separate design constraint when that is the commissioning objective.

Diagnostic transportability changes the interpretation of additional precision. When target specificity fell from 0.86 to 0.80 but validation retained source accuracy, the large-precision-value design had zero coverage in 10,000 simulations despite universal width attainment. Local validation at target specificity restored coverage to 94.83% in that design. Published PHQ-9 analyses have also documented sensitivity bias associated with selective cutoff reporting [21]. These findings support validating the chosen threshold in the intended population before treating a narrower interval as improved inference. S1 Appendix retains the practical decision rules for field implementation.

The informative-response simulation identified a separate failure mechanism: width attainment exceeded 99% while coverage fell to 35.30%–53.43%. Increasing sample size did not correct selection into the responding sample. This finding limits the interpretation of recruitment inflation and supports incorporating response mechanisms into survey analysis and subsequent design evaluation.

Limitations

The empirical basis limits transportability. One Shanghai community sample supplies the screening and validation inputs; discounting its effective sample size does not establish national representativeness. Accuracy against current MINI classification concerns an observed reference standard rather than error-free MDD. The source describes the order of PHQ-9 and MINI administration but does not report their exact elapsed interval. Neither analysed outcome estimates 12-month prevalence. Inconsistencies among the published diagnostic summaries prevent confirmation of an exact validation table. The numerical rounding range cannot provide a sampling confidence interval or quantify between-population accuracy variation.

The design priors, cost ratios, k and λ were investigator-specified. No local pilot, stakeholder valuations, local case-ascertainment costs or nationally representative joint parameter data were available. Reference-positive and reference-negative unit costs must include the resources required to obtain eligible validation participants. The joint optimum therefore establishes a conditional design result, not an optimal national recruitment policy. Its prior-dependence and wider-accuracy scenarios examine selected alternatives rather than estimating transportability.

The precision calculations depend on normal and first-order delta approximations, which may be inaccurate near parameter boundaries or with few diagnostic cases. The joint allocation fixes 67 invitations per cluster and assumes outcome-independent response and independent external validation conditional on the design parameters. It excludes informative cluster size, complex weights, threshold-selection uncertainty and correlated validation sampling. Dividing by RR adjusts expected recruitment yield and cannot remove response bias. The cluster simulations generated screening counts directly rather than individual paired screening and reference diagnoses; their known-accuracy analyses were separate from the finite-validation simulations. The simulations evaluate selected departures and do not validate national transportability or every complex survey design. Parameter assurance and prior-predictive width attainment remain distinct, and observed zero or universal event counts do not establish probabilities of exactly zero or one.

Conclusion

At k = 3, the loss-based rule selected a screening-positive planning proportion of 0.1862 and conditional invitation requirements 39.38% below matched p = 0.5 calculations. Integrating parameter uncertainty increased the screening and current-prevalence invitation targets to 5,346 and 11,866, respectively, with diagnostic accuracy fixed within each current-prevalence scenario. Joint survey–validation allocation increased prior-predictive width attainment from 0.03% to 53.15% at nearly equal assumed cost, and local diagnostic recalibration restored approximately 95% coverage after a specificity shift. Together, these findings show that aligned screening evidence and recruitment losses determine the planning target, while validation allocation and diagnostic calibration shape the precision and validity of current-prevalence estimates.

Supporting information

S1 Appendix. Supplementary methods, proofs, evidence mapping, tables and Fig S1.

(PDF)

pone.0359867.s001.pdf (363.6KB, pdf)
S2 File. Reproducibility code, inputs, numerical outputs and publication figures.

(ZIP)

pone.0359867.s002.zip (18.7MB, zip)

Acknowledgments

The author thanks academic colleagues who commented on earlier versions of the manuscript.

Data Availability

All data are in the manuscript and/or supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–24. doi: 10.1016/S2215-0366(18)30511-X [DOI] [PubMed] [Google Scholar]
  • 2.Lu J, Xu X, Huang Y, Li T, Ma C, Xu G, et al. Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2021;8(11):981–90. doi: 10.1016/S2215-0366(21)00251-0 [DOI] [PubMed] [Google Scholar]
  • 3.Cochran WG. Sampling techniques. 3rd ed. John Wiley & Sons. 1977. [Google Scholar]
  • 4.Adcock CJ. A Bayesian Approach to Calculating Sample Sizes. The Statistician. 1988;37(4/5):433. doi: 10.2307/2348770 [DOI] [Google Scholar]
  • 5.Joseph L, Wolfson DB, Berger RD. Sample Size Calculations for Binomial Proportions via Highest Posterior Density Intervals. The Statistician. 1995;44(2):143. doi: 10.2307/2348439 [DOI] [Google Scholar]
  • 6.Joseph L, M’Lan CE, Wolfson DB. Bayesian sample size determination for binomial proportions. Bayesian Anal. 2008;3(2). doi: 10.1214/08-ba310 [DOI] [Google Scholar]
  • 7.Pham-Gia T, Turkkan N. Sample Size Determination in Bayesian Analysis. The Statistician. 1992;41(4):389. doi: 10.2307/2349003 [DOI] [Google Scholar]
  • 8.Joseph L, du Berger R, Bélisle P. Bayesian and mixed Bayesian/likelihood criteria for sample size determination. Stat Med. 1997;16(7):769–81. doi: 10.1002/(sici)1097-0258(19970415)16:7<769::aid-sim495>3.0.co;2-v [DOI] [PubMed] [Google Scholar]
  • 9.Lindley DV. The choice of sample size. J Royal Statistical Soc D. 1997;46(2):129–38. doi: 10.1111/1467-9884.00068 [DOI] [Google Scholar]
  • 10.Rahme E, Joseph L, Gyorkos TW. Bayesian Sample Size Determination for Estimating Binomial Parameters from Data Subject to Misclassification. Journal of the Royal Statistical Society Series C: Applied Statistics. 2000;49(1):119–28. doi: 10.1111/1467-9876.00182 [DOI] [Google Scholar]
  • 11.Dendukuri N, Rahme E, Bélisle P, Joseph L. Bayesian sample size determination for prevalence and diagnostic test studies in the absence of a gold standard test. Biometrics. 2004;60(2):388–97. doi: 10.1111/j.0006-341X.2004.00183.x [DOI] [PubMed] [Google Scholar]
  • 12.Wang Z, Dendukuri N, Pai M, Joseph L. Taking Costs and Diagnostic Test Accuracy into Account When Designing Prevalence Studies: An Application to Childhood Tuberculosis Prevalence. Med Decis Making. 2017;37(8):922–9. doi: 10.1177/0272989X17713456 [DOI] [PubMed] [Google Scholar]
  • 13.Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wang W, Bian Q, Zhao Y, Li X, Wang W, Du J, et al. Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2014;36(5):539–44. doi: 10.1016/j.genhosppsych.2014.05.021 [DOI] [PubMed] [Google Scholar]
  • 15.Raiffa H, Schlaifer R. Applied statistical decision theory. Division of Research, Graduate School of Business Administration, Harvard University. 1961. [Google Scholar]
  • 16.Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. Int J Epidemiol. 2006;35(5):1292–300. doi: 10.1093/ije/dyl129 [DOI] [PubMed] [Google Scholar]
  • 17.Kish L. Survey sampling. John Wiley & Sons. 1965. [Google Scholar]
  • 18.Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71–6. doi: 10.1093/oxfordjournals.aje.a112510 [DOI] [PubMed] [Google Scholar]
  • 19.Lang Z, Reiczigel J. Confidence limits for prevalence of disease adjusted for estimated sensitivity and specificity. Prev Vet Med. 2014;113(1):13–22. doi: 10.1016/j.prevetmed.2013.09.015 [DOI] [PubMed] [Google Scholar]
  • 20.Alonzo TA, Pepe MS, Lumley T. Estimating disease prevalence in two-phase studies. Biostatistics. 2003;4(2):313–26. doi: 10.1093/biostatistics/4.2.313 [DOI] [PubMed] [Google Scholar]
  • 21.Levis B, Benedetti A, Levis AW, Ioannidis JPA, Shrier I, Cuijpers P, et al. Selective Cutoff Reporting in Studies of Diagnostic Test Accuracy: A Comparison of Conventional and Individual-Patient-Data Meta-Analyses of the Patient Health Questionnaire-9 Depression Screening Tool. Am J Epidemiol. 2017;185(10):954–64. doi: 10.1093/aje/kww191 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Jiaci Lin

16 Jul 2026

Dear Dr. liu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 14 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Jiaci Lin

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

4. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.

5. We notice that your supplementary tables are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: This study presents a potentially valuable methodological framework for sample-size planning in low-prevalence mental health screening surveys. It may have practical implications for public health planning and epidemiological research. However, after careful review, several issues still require further clarification or revision. My specific comments are as follows:

1. The background section should more clearly distinguish between true disorder prevalence and the screening-positive rate.

2. I suggest that the author present the research question earlier and more explicitly. This would help readers grasp the article’s research focus and overall logical flow more quickly.

3. In the discussion, in addition to elaborating on the methodological significance of the proposed methods, the author may also further explore their practical value. For example, the author could describe the contexts in which these methods are applicable and discuss their implications for practice.

4. Some parts of the discussion are repetitive and need to be presented more concisely. In particular, although the discussion of the study’s limitations is comprehensive, it is somewhat list-like. It should be organized more logically.

5. I recommend that the author carefully review and revise the formatting of the entire manuscript, including line spacing and text alignment, in accordance with the journal’s formatting guidelines.

Reviewer #2: - The reported 42.85% sample-size reduction is overstated. Simulations show that p* = 0.173 fails the precision target under higher prevalence, lower specificity or adverse parameters, while p = 0.5 often succeeds; the gain is highly conditional.

- The Beta (15,85) prior relies on only three sources and shifts substantially with moderate heterogeneity, yet guidance for updating is limited.

- The framework depends critically on transportability of Se = Sp = 0.86. When specificity falls to 0.80, precision fails and coverage collapses if original values are assumed; this requires stronger emphasis.

- The cost ratio k = 3 is arbitrary, lacks an elicitation protocol, and materially affects results.

- Equation (8) applies unquantified independence assumptions. The Abstract should qualify results as base-case conditional, the contribution should be framed as integrative, and full code deposition with minor figure/terminology improvements are needed.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Oct 1;21(10):e0359867. doi: 10.1371/journal.pone.0359867.r002

Author response to Decision Letter 1


24 Jul 2026

Dear Reviewers,

Thank you so much for the opportunity to revise the manuscript. I have addressed the reviewers’ concerns about the estimand, interpretation of the calculated sample-size difference, evidential basis of the Beta prior and loss ratio, transportability of PHQ-9 diagnostic accuracy, and assumptions underlying the sample-size equations. These changes required reanalysis as well as revision of the text.

The primary research question remains unchanged: the manuscript evaluates how prior evidence and asymmetric losses can be used to select a planning screening-positive proportion, p_s^\ast, and quantifies the corresponding invited sample size relative to the conventional p=0.5 calculation in a prespecified Chinese depression-surveillance application. The loss ratio k=c_u/c_o is now treated explicitly as an externally specified policy input that should be elicited before sample-size results are examined. Because the present application contains no such elicitation data, k=3 is retained solely as an illustrative base case and is not described as an empirically optimal value.

The revision addresses each substantive point raised by the editor and reviewers. Reference-standard disorder prevalence π is distinguished throughout from the PHQ-9 screening-positive proportion p_s, with separate sample-size equations for the two estimands. The 42.85% difference is reported only as a fixed-input illustration conditional on k=3 and fixed diagnostic accuracy. Beta(15,85) is treated as an evidence-informed planning distribution with prespecified effective sample size, not as a prior estimated from three independent sources. Uncertainty in sensitivity and specificity is propagated through the delta method, including covariance terms for dependent validation designs. The base value k=3 is identified as illustrative, while six prespecified k values are compared without designating a post hoc “best” value. A prospective loss-elicitation protocol has been added. The assumptions governing clustering, unequal cluster size, non-response, diagnostic transportability, parameter dependence and external or nested validation are also stated and examined explicitly.

All numerical results were recomputed from the accompanying reproducibility scripts. Use of the exact Beta transformation and rounding only after the complete calculation changed the base invited sample from 8,718 to 8,717; the conditional percentage difference remains 42.85% after rounding to two decimal places.

Attachment

Submitted filename: Response_to_Reviewers_CORRECTED_v7_2026-07-23.docx

pone.0359867.s004.docx (24.6KB, docx)

Decision Letter 1

Jiaci Lin

28 Aug 2026

Dear Dr. liu,

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 26 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS One offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Jiaci Lin

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: The author has responded carefully to the comments raised in the previous round of review, and the revised manuscript has improved substantially.

However, one issue still requires clarification. The manuscript uses the 12-month MDD prevalence estimate, together with the sensitivity and specificity of the PHQ-9, to anchor the planning distribution for the expected PHQ-9 screening-positive proportion. The standard PHQ-9, however, primarily assesses depressive symptoms experienced over the past two weeks. It is therefore unclear whether the PHQ-9 screening-positive proportion and the 12-month reference-standard MDD prevalence are temporally aligned estimands and whether the cited sensitivity and specificity estimates support this mapping.

Reviewer #2: Dear Authors,

The revised version is acceptable and the necessary corrections have been made.

Good luck.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Oct 1;21(10):e0359867. doi: 10.1371/journal.pone.0359867.r004

Author response to Decision Letter 2


8 Sep 2026

Dear Dr Lin,

Thank you for the further review. The revision replaces the annual-prevalence-based screening anchor and updates the dependent calculations. The principal changes and the response to the remaining temporal-alignment concern are detailed below.

Page and line references identify the PLOS submission edition (Manuscript.docx; 28-page clean rendering) dated 8 September 2026. Supplementary page references identify S1 Appendix. The marked manuscript records changes relative to the uploaded R1 clean manuscript.

Summary of the main revisions

Evidence and outcomes. The screening prior now uses observed PHQ-9 positivity. The 12-month national estimate is retained solely as background, and current MINI-defined prevalence is analysed as a separate outcome. See Methods, pp. 4–6, and S1 Appendix, Section S9, pp. 7–8.

Recalculation and diagnostic validation. Revised inputs were propagated through the sample-size calculations, sensitivity analyses and simulations. Joint recruitment–validation allocation and its operating characteristics are reported separately from conditional planning. See Results, pp. 14–21, Tables 1–5 and Figures 1–4.

Reporting and interpretation. Methods specifies the executed analysis steps; Results follows the calculation sequence; Discussion interprets those results; and the Conclusion answers the study aim. See Methods, pp. 4–14; Discussion, pp. 21–23; and Conclusion, p. 24.

References and reproducibility. References and source-to-input links were checked. The package includes the original-R1 Word comparison, a clean manuscript, the supporting derivations, and executable code with numerical and simulation outputs.

Reviewer 1: the 12-month prevalence and two-week PHQ-9 concern

Comment.

The author has responded carefully to the comments raised in the previous round of review, and the revised manuscript has improved substantially. However, one issue still requires clarification. The manuscript uses the 12-month MDD prevalence estimate, together with the sensitivity and specificity of the PHQ-9, to anchor the planning distribution for the expected PHQ-9 screening-positive proportion. The standard PHQ-9, however, primarily assesses depressive symptoms experienced over the past two weeks. It is therefore unclear whether the PHQ-9 screening-positive proportion and the 12-month reference-standard MDD prevalence are temporally aligned estimands and whether the cited sensitivity and specificity estimates support this mapping.

Response. The original mapping lacked accuracy estimates validated against a 12-month reference target. The correction therefore changes the empirical anchor, outcome definitions and dependent analyses. It is implemented in Methods and Results, with the remaining source limitations identified separately.

1. The annual prevalence estimate was removed from the analysis inputs

The national 12-month MDD estimate no longer enters prior construction, specificity recalibration, parameter draws or simulation scenarios. The Introduction retains the weighted estimate of 2.1% as epidemiological background and corrects its 95% confidence interval to 1.8%–2.4%, as reported in Table 2 of Huang et al. (2019). The prior construction no longer triangulates screening yield from annual prevalence sources.

Location. Introduction, p. 3, lines 37–43; Methods, “Planning prior and updating,” pp. 5–6, lines 107–110; S1 Appendix, Section S9 and Table S7, pp. 7–8.

2. The screening prior was rebuilt from directly observed PHQ-9 results

At PHQ-9 ≥7, the Shanghai validation study reported 170 screening-positive results among 1,045 community participants (Wang et al., 2014, Section 3.3 and Table 1). The revised screening prior uses their observed proportion, 170/1,045 = 0.162679, without converting a disorder-prevalence estimate into screening positivity. Retaining the specified ESS of 100 gives Beta(16.2679426, 83.7320574), replacing Beta(15, 85). ESS remains an investigator-specified discount rather than an estimated national sample size.

Location. Methods, “Planning prior and updating,” pp. 5–6, lines 107–110; Figure 1A; S1 Appendix, Table S7, pp. 7–8; input_provenance.csv.

3. The reference-prevalence analysis was defined separately and indexed to its target

Methods now distinguishes S2w, PHQ-9 positivity for symptoms over the preceding two weeks, from Dcur, the current MINI depression reference classification. Equation (1) uses Se = P(S2w = 1 | Dcur = 1) and Sp = P(S2w = 0 | Dcur = 0). The same study reported 28 MINI-positive participants and threshold-specific sensitivity and specificity of 0.86 (Wang et al., 2014, Sections 3.1 and 3.3; Table 4). These aggregates define the current-reference illustration; current-prevalence parameter draws generate screening positivity from Equation (1).

The source reports PHQ-9 administration followed by MINI assessment and describes the MINI reference in relation to current major depressive episodes (Wang et al., 2014, Sections 2.2–2.3.2). Its two-week follow-up in 100 participants concerned PHQ-9 test–retest reliability (Wang et al., 2014, Section 2.2). That follow-up does not establish the elapsed interval between PHQ-9 and MINI administration, which the source does not specify.

A 12-month prevalence analysis would instead require sensitivity P(S2w = 1 | D12m = 1) and specificity P(S2w = 0 | D12m = 0), where D12m identifies a reference-standard episode during that year. Such annual-reference accuracy was not established by the cited study. The revised numerical analysis therefore concerns directly observed screening positivity and a separate current reference outcome; neither is presented as 12-month MDD prevalence.

Location. Methods, “Estimands and measurement relation,” p. 4, lines 73–84; Equation (1); Methods, “Joint parameter assurance,” p. 10, lines 198–214; S1 Appendix, Section S9, pp. 7–8; Limitations, p. 23, lines 479–486.

4. All dependent numerical results were updated

At the unchanged illustrative loss ratio k = 3, the revised planning proportion is 0.1862346, compared with 0.1727 in R1. Conditional screening invitations increased from 4,519 to 4,794, and current-reference invitations with fixed diagnostic accuracy increased from 8,717 to 9,247. The updated differences from matched p = 0.5 calculations are 39.38%. Integrating uncertainty over the full invitation requirement separately selects 5,346 screening and 11,866 current-reference invitations, with diagnostic accuracy fixed within each current-reference scenario. Sensitivity analyses, simulations, figures, the Abstract and the Conclusion use the revised inputs and outputs.

Location. Results, “Planning value and base-case sample sizes,” p. 14, lines 300–309; Table 1; Results, pp. 15–21; Abstract, p. 2; Conclusion, p. 24, lines 505–513; S1 Appendix, Table S1.

5. The empirical evidence and unresolved source details were made traceable

Table S7 maps each count, diagnostic-accuracy estimate and time-window definition to its source section and analytical use. The directly observed screening mean, 0.162679, is distinguished from the model-implied reference-point probability, 0.159292, calculated using 28/1,045 and rounded Se = Sp = 0.86. Source counts were not altered to force agreement. The source audit also records inconsistencies among published diagnostic summaries. No author-confirmed complete diagnostic table or participant-level dataset is claimed. Sampling uncertainty and population transportability are evaluated separately from numerical rounding.

Location. S1 Appendix, Section S7, p. 5, and Section S9/Table S7, pp. 7–8; Limitations, p. 23, lines 479–486; input_provenance.csv.

Reviewer 2

Comment. “The revised version is acceptable and the necessary corrections have been made.”

Response. Thank you for this assessment. The additional changes prompted by Reviewer 1 have been checked for consistency across the manuscript, supporting analyses and figures.

Further revisions and journal requirements

Methods, decision criteria and validation precision

The study aim is stated at the end of the Introduction. Methods specifies the input distributions, loss ratios, sensitivity grids, random streams, estimators and performance metrics. Conditional recruitment, parameter assurance and simulated interval-width attainment are distinguished. Equations (10)–(11) define the independent-validation variance budget and its feasibility boundary; the reference-point half-width floor is 0.0292, above the 0.020 target. Equations (13)–(15) add decisions over the full recruitment requirement and joint survey–validation allocation, with proofs for the stated objectives in S1 Appendix.

Joint allocation achieved 53.15% prior-predictive width attainment, compared with 0.03% when a nearly equal assumed budget retained the original validation counts. Costs, priors and precision valuations are identified as assumptions. The Discussion distinguishes optimality for the specified risk from attaining a prespecified probability of adequate precision. Operational steps are reported in Methods; response bias, simulation scope and transportability restrictions appear in Limitations.

Location. Introduction, p. 4, lines 66–70; Methods, pp. 7–14; Methods, “Bayes decisions under joint uncertainty” and “Joint allocation of survey and validation samples,” pp. 10–12, lines 215–251; Equations (13)–(15); Table 5 and Figure 4; Discussion, pp. 21–23, lines 436–477; Limitations, pp. 23–24, lines 479–503.

Results, figures, Discussion and Conclusion

Reporting request. “The results section is difficult to follow in its current form. Key findings should be presented more clearly and systematically, with improved figure quality and more transparent reporting.”

Results now proceeds from the planning value and conditional invitation counts to joint parameter assurance, prior sensitivity, diagnostic-validation precision, simulation performance and joint allocation. Tables identify the estimand and precision metric, and the long simulation passages are divided by function. Discussion interprets the corresponding findings. The Conclusion answers the research aim using the recalculated recruitment, validation-allocation and calibration results. Figures 1–4 and S1 are supplied as 600 dpi TIFFs with vector PDF copies; simulation figures include Monte Carlo intervals. Table labels are non-italic, and the full titles of Figures 1 and 2 are bold.

Location. Results, pp. 14–21, Tables 1–5 and Figures 1–4; Discussion, pp. 21–23, lines 436–477; Conclusion, p. 24, lines 505–513.

Reference corrections

All 21 manuscript references were matched to the in-text citations in both directions. Grouped literature citations were replaced by one source per cited sentence. The revised bibliography adds the original PHQ-9 instrument paper, a two-phase prevalence-estimation paper and a study of selective cutoff reporting. Two prevalence reviews used in the former annual-prevalence triangulation and one unused general decision-theory source were removed. Source scope and bibliographic details were checked, including the national prevalence confidence interval and the Shanghai assessment protocol. The PLOS manuscript uses numbered references in order of first appearance; the APA edition uses author–year citations.

Location. Introduction and References; citation_statement_map.csv; citation_audit.csv; S1 Appendix, Table S7.

Submission files and reproducibility

The package supplies separate files labelled Response to Reviewers, Revised Manuscript with Track Changes and Manuscript. The native Word comparison uses the original clean R1 manuscript corresponding to pages 8–33 of the uploaded submission PDF. Accepting its content revisions reproduces the current clean manuscript; rejecting them restores the R1 content. The comparison is reconstructed from the two versions and retains the revised page layout.

S1 Appendix supplies the derivations, simulation specifications and source mapping. S2_Reproducibility.zip contains the executed analysis script, software requirements, numerical outputs and replicate arrays. The computational record reproduces the declared aggregate-input illustration and distinguishes simulated observations from participant data. The funding and competing-interest declarations are retained.

Location. Data and code availability, p. 25, lines 521–526; Declarations; S1 Appendix; S2_Reproducibility; original_comparison.json.

Sincerely,

Han Liu

Attachment

Submitted filename: Response_to_Reviewers(8).docx

pone.0359867.s005.docx (25.6KB, docx)

Decision Letter 2

Jiaci Lin

20 Sep 2026

Decision-theoretic recruitment and validation planning for depression surveys: an illustrative Chinese application

PONE-D-26-26922R2

Dear Dr. liu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jiaci Lin

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

**********

Reviewer #1: The revised manuscript is acceptable. The author have carefully addressed all the comments and suggestions raised during the previous review stage.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

**********

Acceptance letter

Jiaci Lin

PONE-D-26-26922R2

PLOS One

Dear Dr. liu,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS One and supporting open access.

Kind regards,

PLOS One Editorial Office Staff

on behalf of

Dr. Jiaci Lin

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Supplementary methods, proofs, evidence mapping, tables and Fig S1.

    (PDF)

    pone.0359867.s001.pdf (363.6KB, pdf)
    S2 File. Reproducibility code, inputs, numerical outputs and publication figures.

    (ZIP)

    pone.0359867.s002.zip (18.7MB, zip)
    Attachment

    Submitted filename: Response_to_Reviewers_CORRECTED_v7_2026-07-23.docx

    pone.0359867.s004.docx (24.6KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers(8).docx

    pone.0359867.s005.docx (25.6KB, docx)

    Data Availability Statement

    All data are in the manuscript and/or supporting information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES